Related Experiment Video

Updated: Jun 8, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Association between abacavir exposure and increased risk for cardiovascular disease in patients with human

Jason J Schafer1, William R Short, Kathleen E Squires

  • 1Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-5233, USA. jason.schafer@jefferson.edu

Pharmacotherapy
|September 30, 2010
PubMed

Insights

Human immunodeficiency virus (HIV) infection and antiretroviral therapy are linked to cardiovascular disease. Abacavir, an HIV drug, may also increase cardiovascular risks, warranting careful patient evaluation.

Area of Science:

  • Infectious Diseases
  • Cardiology
  • Pharmacology

Background:

  • HIV infection and antiretroviral therapy (ART) are associated with increased cardiovascular disease (CVD) risk.
  • Treatment-induced dyslipidemia, insulin resistance, and body composition changes contribute to CVD in HIV patients.
  • Protease inhibitors and thymidine analogs (stavudine, zidovudine) are implicated in these complications.

Purpose of the Study:

  • To investigate the potential association between abacavir exposure and cardiovascular disease events in HIV-infected patients.
  • To inform current guidelines regarding abacavir use in high-risk cardiovascular disease patients.

Main Methods:

  • Review of recent investigations and clinical findings.
  • Analysis of patient data to assess abacavir's role in cardiovascular events.

Main Results:

  • Emerging evidence suggests a link between abacavir exposure and cardiovascular disease events.
  • Current guidelines recommend caution with abacavir in high-risk cardiovascular disease patients.

Conclusions:

  • Abacavir's association with cardiovascular disease requires further investigation.
  • Individualized risk-benefit assessments are crucial when considering abacavir regimen changes.
  • More research is needed to clarify the roles of HIV infection and specific antiretroviral agents in CVD development.

More Related Videos

An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells07:39

An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells

Published on: August 15, 2012

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...